Last updated: July 20, 2021
Sponsor: Axsome Therapeutics, Inc.
Overall Status: Active - Enrolling
Phase
2
Condition
Depression (Adult And Geriatric)
Mood Disorders
Depression (Major/severe)
Treatment
N/AClinical Study ID
NCT04971291
AXS-05-TRD-203
Ages 18-65 All Genders
Study Summary
Eligibility Criteria
Inclusion
Key Inclusion Criteria:
- Provided written informed consent to participate in Study AXS-05-301
- Has treatment-resistant depression, defined as an inadequate response to 2 or 3 priorADTs
- Body mass index (BMI) between 18 and 40 kg/m2, inclusive
Exclusion
Key Exclusion Criteria:
- Suicide risk
- Treatment with any investigational drug within 6 months
- History of electroconvulsive therapy (ECT), vagus nerve stimulation, transcranialmagnetic stimulation, or any experimental central nervous system treatment during thecurrent episode or in the past 6 months
- Pregnant, breastfeeding, or planning to become pregnant or breastfeed during the study
Study Design
Total Participants: 312
Study Start date:
April 14, 2021
Estimated Completion Date:
July 31, 2021
Connect with a study center
Axsome Research Site
New York, New York 10007
United StatesSite Not Available
Not the study for you?
Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.